ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1844

Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries

Polina Putrik1, Sofia Ramiro2, Milena Pavlova3, Tore K. Kvien4, Tuulikki Sokka5, Till Uhlig4, Annelies Boonen6 and Equity In Access To Treatment of RA Across Europe7, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, 3Health Services Research, Maastricht University, Maastricht, Netherlands, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 6Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 7European Region

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Access to care, Disease-modifying antirheumatic drugs, rheumatoid arthritis, treatment and socioeconomic factors

  • Tweet
  • Email
  • Print
Session Information

Session Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is not known to what extent limited access to these drugs can hamper implementation of the EULAR recommendations. A poor ability to adhere to these recommendations might contribute to health disparities previously seen in RA patients across countries [1]. The purpose of the study was to explore access to biologics across Europe along the three dimensions of access: availability, affordability and acceptability.

Methods:

Number of reimbursed drugs, prices of biologics, and data on cultural acceptability of biologics were collected by questionnaire sent to one representative rheumatologist in 49 countries of the European Region. To ensure comparability, national prices were converted into international dollars ($) to adjust for the countries’ purchasing power parity (PPP). Data on socio-economic welfare (gross domestic product (GDP), health expenditure, median income and minimum wage) were retrieved from web-based sources. Data on RA health status (DAS28, HAQ, TJC, SJC, ESR) were retrieved from the literature (QUEST RA) [1]. Indicators of access in each axis were correlated with indicators of welfare and RA health status using Spearman correlations.

Results:

In total, 46 countries (response rate 94%) provided data. With respect to availability, in 10 countries no biologics were reimbursed, while 5 or more were reimbursed in 27 countries. With respect to affordability, annual average prices per patient of all available biologics varied from €9,431 (Turkey) to €21,349 (Germany), corresponding to a price ratio of 2.3. However, after adjusting the prices for PPPs, prices ranged from int.$14,446 to int.$61,552 (price ratio 4.3). Cultural acceptability ranged from 0 to 10 (10 poorest acceptability). Number of reimbursed drugs showed moderate to very strong positive correlation with the economic welfare and inverse correlation with the RA health status. While national prices seemed to be slightly lower in low income countries, after adjusting to PPP prices were strongly inversely correlated with economic welfare and positively with RA health. The sum-score of the acceptability was negatively associated with the economic indicators, and positively with the RA health status (table).

 

Range

Mean (SD)

Median

Correlations with GDP

Correlations with median income

Correlations with mean DAS28

Correlations with SCJ

Total number

of biologics

reimbursed

0-8

4.9 (3.3)

7

0.88

0.59

-0.78

-0.61

Average

annual price

of biologics,

int.$

14,446 -61,552

28,548.1 (10,768.5)

27,632.13

-0.84

-0.75

0.75

0.72

Average acceptability score

0-10

5.1 (3.3)

2.5

-0.63

-0.37

0.69

0.71

Conclusion:

European countries with lower socio-economic status seem to have less access to biologics in terms of lower availability, affordability and acceptability (more barriers), while health of RA patients is worse. This implies inequity in access for innovative care disfavoring patients in poorer societies.

References: [1].Sokka T et al. Ann Rheum Dis 2009;68,1666-72


Disclosure:

P. Putrik,
None;

S. Ramiro,
None;

M. Pavlova,
None;

T. K. Kvien,
None;

T. Sokka,

Grants from Academy of Finland and Abbott, the QUEST-RA invesigators,

2;

T. Uhlig,
None;

A. Boonen,
None;

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inequities-in-access-to-biologic-disease-modifying-anti-rheumatic-drugs-for-patients-with-rheumatoid-arthritis-across-46-european-countries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies